blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3156420

EP3156420 - HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  27.12.2019
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  18.01.2019
FormerGrant of patent is intended
Status updated on  25.06.2018
FormerExamination is in progress
Status updated on  17.11.2017
FormerRequest for examination was made
Status updated on  27.10.2017
FormerThe application has been published
Status updated on  20.03.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Seattle Genetics, Inc.
21823 30th Drive, S.E.
Bothell, WA 98021 / US
[2017/16]
Inventor(s)01 / SMITH, Maria Leia
21823 30th Drive, S.E.
Bothell, WA Washington 98021 / US
02 / SUSSMAN, Django
21823 30th Drive, S.E.
Bothell, WA Washington 98021 / US
03 / ARTHUR, William
21823 30th Drive, S.E.
Bothell, WA Washington 98021 / US
04 / NESTEROVA, Albina
21823 30th Drive, S.E.
Bothell, WA Washington 98021 / US
 [2017/16]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2019/08]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2017/16]Roques, Sarah Elizabeth
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date16200557.306.12.2011
[2017/16]
Priority number, dateUS20100420291P06.12.2010         Original published format: US 420291 P
US201161446990P25.02.2011         Original published format: US 201161446990 P
[2017/16]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3156420
Date:19.04.2017
Language:EN
[2017/16]
Type: B1 Patent specification 
No.:EP3156420
Date:20.02.2019
Language:EN
[2019/08]
Search report(s)(Supplementary) European search report - dispatched on:EP25.01.2017
ClassificationIPC:C07K16/28, C07K16/30, A61K39/395, C12P21/08, A61K35/00
[2017/16]
CPC:
C07K16/28 (EP,IL,KR,RU,US); A61K47/6865 (EP,IL,KR,US); A61P13/08 (EP,IL);
A61P15/00 (EP,IL); A61P17/00 (EP,IL); A61P35/00 (EP,IL,KR);
C07K16/3015 (EP,IL,KR,US); C07K16/3053 (IL,KR,US); C07K16/3069 (EP,IL,KR,US);
C07K16/465 (EP,IL,US); A61K2039/505 (EP,IL,KR,US); C07K2317/24 (EP,IL,KR,US);
C07K2317/52 (IL,KR,US); C07K2317/56 (IL,US); C07K2317/565 (EP,IL,KR,US);
C07K2317/732 (IL,KR,US); C07K2317/92 (EP,IL,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/48]
Former [2017/16]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:HUMANISIERTE ANTIKÖRPER GEGEN LIV-1 UND VERWENDUNG DAVON ZUR BEHANDLUNG VON KREBS[2017/16]
English:HUMANIZED ANTIBODIES TO LIV-1 AND USE OF SAME TO TREAT CANCER[2017/16]
French:ANTICORPS HUMANISÉS À LIV-1 ET LEUR UTILISATION POUR TRAITER LE CANCER[2017/16]
Examination procedure24.11.2016Date on which the examining division has become responsible
19.10.2017Amendment by applicant (claims and/or description)
19.10.2017Examination requested  [2017/48]
15.11.2017Despatch of a communication from the examining division (Time limit: M04)
21.03.2018Reply to a communication from the examining division
26.06.2018Communication of intention to grant the patent
05.11.2018Fee for grant paid
05.11.2018Fee for publishing/printing paid
05.11.2018Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP11847198.6  / EP2648752
Divisional application(s)EP18204152.5  / EP3461847
EP20189823.6  / EP3786185
Opposition(s)21.11.2019No opposition filed within time limit [2020/05]
Fees paidRenewal fee
24.11.2016Renewal fee patent year 03
24.11.2016Renewal fee patent year 04
24.11.2016Renewal fee patent year 05
24.11.2016Renewal fee patent year 06
27.12.2017Renewal fee patent year 07
31.12.2018Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL20.02.2019
EE20.02.2019
HR20.02.2019
LT20.02.2019
LV20.02.2019
MC20.02.2019
MK20.02.2019
MT20.02.2019
RS20.02.2019
SM20.02.2019
BG20.05.2019
IS20.06.2019
[2022/32]
Former [2021/34]AL20.02.2019
EE20.02.2019
HR20.02.2019
LT20.02.2019
LV20.02.2019
MC20.02.2019
MT20.02.2019
RS20.02.2019
SM20.02.2019
BG20.05.2019
IS20.06.2019
Former [2020/39]AL20.02.2019
EE20.02.2019
HR20.02.2019
LT20.02.2019
LV20.02.2019
MC20.02.2019
RS20.02.2019
SM20.02.2019
BG20.05.2019
IS20.06.2019
Former [2019/52]AL20.02.2019
EE20.02.2019
HR20.02.2019
LT20.02.2019
LV20.02.2019
RS20.02.2019
SM20.02.2019
BG20.05.2019
IS20.06.2019
Former [2019/49]AL20.02.2019
EE20.02.2019
HR20.02.2019
LT20.02.2019
LV20.02.2019
RS20.02.2019
BG20.05.2019
IS20.06.2019
Former [2019/39]HR20.02.2019
LT20.02.2019
LV20.02.2019
RS20.02.2019
BG20.05.2019
IS20.06.2019
Former [2019/38]LT20.02.2019
BG20.05.2019
Former [2019/33]LT20.02.2019
Documents cited:Search[I]WO2004067564  (PROTEIN DESIGN LABS INC [US], et al);
 [A]WO2005058961  (AMGEN INC [US], et al);
 [X]WO2008131376  (WYETH CORP [US], et al)
by applicantUS4634664
 US4634666
 US4880935
 WO8912624
 WO9110741
 WO9117271
 WO9201047
 US5122368
 WO9312227
 US5225539
 US5530101
 US5545806
 US5565332
 US5569825
 US5585089
 US5622929
 US5624821
 US5625126
 US5633425
 US5661016
 US5733743
 US5770429
 US5789650
 US5814318
 US5824805
 US5834597
 US5837242
 US5859205
 US5858657
 US5871907
 US5874299
 US5877397
 US5877218
 US6130237
 US6214345
 US6407213
 US6624821
 WO2004010957
 US2004141983
 US6881557
 US2005238649
 WO2006036291
 US2006074008
 US2008175839
 US2009317869
 US2010158909
 US2010158919
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.